

News Center
All
2025
2024
2023
2022
2021
2020
-
LaNova Medicines Initiates Pivotal Clinical Trial for LM-108 in China2024-12-20
Learn More
-
LaNova Medicines Announces Global Exclusive License Agreement with Merck for LM-299, an Investigational Anti-PD-1/VEGF Bispecific Antibody2024-11-14
Learn More
-
LaNova Medicines and CTTQ Announces the IND Approval of Combination Therapies by NMPA2024-10-09
Learn More
-
LaNova Medicines Announces the IND Approval of LM-299 by NMPA2024-07-11
Learn More
-
LaNova Medicines Announces IND Approval of LM-317 by US FDA2024-06-10
Learn More
-
LaNova Medicines Initiates First Phase III Clinical Trial for LM-302 in China2024-04-11
Learn More